X4 Pharmaceuticals’ (XFOR) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR) in a report published on Wednesday,Benzinga reports. They currently have a $3.00 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $1.50 price target on shares of X4 Pharmaceuticals in a research report on Friday, February 7th.

X4 Pharmaceuticals Trading Down 7.8 %

Shares of X4 Pharmaceuticals stock opened at $0.25 on Wednesday. X4 Pharmaceuticals has a twelve month low of $0.24 and a twelve month high of $1.60. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The business has a 50-day moving average price of $0.43 and a 200-day moving average price of $0.52. The firm has a market cap of $43.42 million, a price-to-earnings ratio of -2.78 and a beta of 0.39.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The company had revenue of $1.43 million during the quarter, compared to the consensus estimate of $1.07 million. Equities research analysts anticipate that X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Adam S. Mostafa sold 74,773 shares of X4 Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $33,647.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Paula Ragan sold 76,473 shares of the stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the sale, the chief executive officer now owns 1,087,386 shares in the company, valued at $489,323.70. The trade was a 6.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 202,663 shares of company stock valued at $91,198 over the last ninety days. 1.62% of the stock is owned by insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Bank of America Corp DE grew its holdings in X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after purchasing an additional 22,485 shares during the last quarter. Point72 Asset Management L.P. grew its stake in shares of X4 Pharmaceuticals by 4.0% during the fourth quarter. Point72 Asset Management L.P. now owns 650,000 shares of the company’s stock valued at $477,000 after buying an additional 24,948 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of X4 Pharmaceuticals by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock worth $58,000 after buying an additional 26,763 shares during the period. Northern Trust Corp lifted its stake in shares of X4 Pharmaceuticals by 2.9% during the 4th quarter. Northern Trust Corp now owns 1,357,539 shares of the company’s stock worth $996,000 after acquiring an additional 37,940 shares during the last quarter. Finally, Cantor Fitzgerald L. P. purchased a new position in X4 Pharmaceuticals during the 4th quarter valued at $30,000. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.